TriangleVorasidenib (NCT07286292)
Vorasidenib trial for Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation (NCT07286292). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for children aged 12–17, weighing at least 25 kilograms, with grade-two astrocytoma or oligodendroglioma and an IDH1 or IDH2 mutation. Only prior surgery is allowed; immediate chemotherapy or radiation must not be needed.
The idea: vorasidenib blocks altered IDH enzymes and reduces a tumor-growth chemical. Daily oral doses are 20 milligrams below 40 kilograms, or 40 milligrams at higher weights. Researchers assess safety, growth, puberty and tumor effects, with follow-up.
This phase 2 study plans 10 patients. Servier sponsors it; four US sites are recruiting, including Los Angeles.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.